The Ongoing Evolution of Optimal Clinical Endpoints for Heart Failure Trials

被引：2

作者：

Krum, Henry ^{[1
]}

Hopper, Ingrid ^{[1
]}

机构：

[1] Monash Univ, Sch Publ Hlth & Prevent Med, Ctr Cardiovasc Res & Educ Therapeut, Melbourne, Vic 3004, Australia

来源：

JACC-HEART FAILURE | 2015年 / 3卷 / 08期

关键词：

beta-blockers; clinical trials; endpoints; mortality; MORTALITY; MORBIDITY;

D O I：

10.1016/j.jchf.2015.04.010

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：615 / 617

页数：3

共 13 条

[1] The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials [J].

Anker, Stefan D. ;

Agewall, Stefan ;

Borggrefe, Martin ;

Calvert, Melanie ;

Caro, J. Jaime ;

Cowie, Martin R. ;

Ford, Ian ;

Paty, Jean A. ;

Riley, Jillian P. ;

Swedberg, Karl ;

Tavazzi, Luigi ;

Wiklund, Ingela ;

Kirchhof, Paulus .

EUROPEAN HEART JOURNAL, 2014, 35 (30) :2001-+

[2] How to assess new treatments for the management of heart failure: composite scoring systems to assess the patients' clinical journey [J].

Cleland, JGF .

EUROPEAN JOURNAL OF HEART FAILURE, 2002, 4 (03) :243-247

[3] Unconventional End Points in Cardiovascular Clinical Trials: Should We Be Moving Away From Morbidity and Mortality? [J].

Cohn, Jay ;

Cleland, John G. F. ;

Lubsen, Jacobus ;

Borer, Jeffrey S. ;

Steg, Philippe Gabriel ;

Perelman, Michael ;

Zannad, Faiez .

JOURNAL OF CARDIAC FAILURE, 2009, 15 (03) :199-205

[4]

Eichhorn E, 2001, NEW ENGL J MED, V344, P1659

[5]

Hjalmarson Å, 1999, LANCET, V353, P2001

[6]

Lechat P, 1999, LANCET, V353, P9

[7] Effect of carvedilol on the morbidity of patients with severe chronic heart failure - Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study [J].

Packer, M ;

Fowler, MB ;

Roecker, EB ;

Coats, AJS ;

Katus, HA ;

Krum, H ;

Mohacsi, P ;

Rouleau, JL ;

Tendera, M ;

Staiger, C ;

Holcslaw, T ;

Amann-Zalan, I ;

DeMets, DL .

CIRCULATION, 2002, 106 (17) :2194-2199

[8] Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure [J].

Packer, M .

JOURNAL OF CARDIAC FAILURE, 2001, 7 (02) :176-182

[9]

Perry G, 1997, NEW ENGL J MED, V336, P525

[10] The effect of spironolactone on morbidity and mortality in patients with severe heart failure [J].

Pitt, B ;

Zannad, F ;

Remme, WJ ;

Cody, R ;

Castaigne, A ;

Perez, A ;

Palensky, J ;

Wittes, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (10) :709-717

← 1 2 →